Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Feb18.pdf
   Google Scholar
• Cheng XLJ, Zhang Z. The relationship between smoking and the incidence of COPD. Chin J Tuberc Respir Dis. 1999;22(5):290–292.
   Google Scholar
• Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest. 2011;139(4):920–929.
   PubMed Web of Science ®Google Scholar
• Li Q, Hsia J, Yang G. Prevalence of smoking in China in 2010. N Engl J Med. 2011;364(25):2469–2470.
   PubMed Web of Science ®Google Scholar
• Yu WC, Fu SN, Tai EL, Yeung YC, Kwong KC, Chang Y, et al. Spirometry is underused in the diagnosis and monitoring of patients with chronic obstructive pulmonary disease (COPD). Int J Chron Obstruct Pulmon Dis. 2013;8:389–395.
   PubMed Web of Science ®Google Scholar
• Huang K, Wang C, Han J, Zheng J, Dai L, INTACT Study Investigators. Current maintenance treatment of chronic obstructive pulmonary disease in China. Eur Respir J. 2014;44(Suppl 58):P4108.
   Google Scholar
• Zhang L, Lou P, Zhu Y, Chen P, Zhang P, Yu J, et al. Impact of risk factors, activities and psychological disorders on the health of patients with chronic obstructive pulmonary disease in China: a cross-sectional study. BMC Public Health. 2013;13:627.
   PubMed Web of Science ®Google Scholar
• Respiratory Diseases Branch of Chinese Medical Association. A national guideline for the diagnosis m, and prevention of chronic obstructive pulmonary disease in China (in Chinese). Chin J Tuberc Respir Dis. 2007;30:9–317.
   Google Scholar
• Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494.
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.
   PubMed Web of Science ®Google Scholar
• Banerji D, Fedele MJ, Chen H, Kim HJ. Dual bronchodilation with QVA149 reduces COPD exacerbations: results from the IGNITE program (OS36: COPD 3). Respirology. 2013;18:69–70.
   Web of Science ®Google Scholar
• Martin A, Badrick E, Mathur R, Hull S. Effect of ethnicity on the prevalence, severity, and management of COPD in general practice. Br J Gen Pract. 2012;62(595):e76–81.
   Google Scholar
• Asai K, Minakata, Y., Hirata, K., Fukuchi, Y., Kitawaki, T., Ikeda, K., Banerji, D. QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study. Eur Respir J. 2013;42(57 Suppl):3392.
   Google Scholar
• Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1(3):199–209.
   PubMed Web of Science ®Google Scholar
• Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J COPD. 2015;10.
   Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007(4):CD006829.
   Google Scholar
• GOLD. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2014. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jun11.pdf
   Google Scholar
• Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009;34(1):13–16.
   PubMed Web of Science ®Google Scholar
• de Miguel-Diez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martin-Centeno A, Gobartt-Vazquez E, Hernandez-Barrera V, et al. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung. 2011;189(3):199–206.
   PubMed Web of Science ®Google Scholar
• Rupert Jones NF, Marc Miravitlles, Guy Bruselle, Kevin Gruffydd-Jones, Mike Baldwin, Rebecca Stewart, Anna Rigazio, Annie Burden and David Price. Inappropriate prescriptions following initial COPD diagnosis. Eur Respir J. 2013;42(57 Suppl):P2391.
   Google Scholar
• DiSantostefano RL, Sampson T, Le HV, Hinds D, Davis KJ, Bakerly ND. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS One. 2014;9(5):e97149.
   PubMed Web of Science ®Google Scholar
• Weatherall M, James K, Clay J, Perrin K, Masoli M, Wijesinghe M, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008;38(9):1451–1458.
   PubMed Web of Science ®Google Scholar
• Herth FJ, Bramlage P, Muller-Wieland D. Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease. Respiration 2015;89(1):66–75.
   PubMed Web of Science ®Google Scholar
• Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337(1):8–14.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest. 2013;143(4):1018–1024.
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Guerrero M, Menendez R, Huerta A, Martinez R, Gimeno A, et al. Inhaled corticosteroids do not influence the early inflammatory response and clinical presentation of hospitalized subjects with COPD exacerbation. Respir Care. 2014;59(10):1550–1559.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294.
   PubMed Web of Science ®Google Scholar
• Rossi A, Guerriero M, Corrado A, Group OAS. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15:77.
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, Olmo RD, Papi A, Wehbe L, Quinn M, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556.
   PubMed Web of Science ®Google Scholar
• Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19(116):113–118.
   PubMedGoogle Scholar
• Price D, Keininger D, Baldwin M, Mezzi K, Asukai Y, Ställberg B. Cost-effectiveness of the LABA/LAMA dual bronchodilator QVA149 in a Swedish setting. Eur Respir J. 2013;42(Suppl 57):P280.
   Google Scholar
• Geitona M, Kousoulakou H, Kalogerolpoulou M, Mistiki E, Steiropoulos P. Cost effectiveness of the fixed combination of indacaterol/glycopyrronium versus salmeterol/ fluticasone and tiotropium in the management of patients with COPD in Greece. J Health Policy Oucome Res. 2015;1:56–65.
   Google Scholar
• Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, et al. Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD. Ann Am Thorac Soc. 2015;12(1):27–34.
   PubMed Web of Science ®Google Scholar
• Weldam SW, Lammers JW, Heijmans MJ, Schuurmans MJ. Perceived quality of life in chronic obstructive pulmonary disease patients: a cross-sectional study in primary care on the role of illness perceptions. BMC Fam Pract. 2014;15:140.
   PubMed Web of Science ®Google Scholar